Clinical Trial Detail

NCT ID NCT03150329
Title Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors City of Hope Medical Center
Indications

Hodgkin's lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Pembrolizumab + Vorinostat

Age Groups: adult senior

No variant requirements are available.